EM 1034
Alternative Names: EM-1034Latest Information Update: 28 Nov 2025
At a glance
- Originator EpimAb Biotherapeutics
- Class Antineoplastics; Bispecific antibodies; Immunotherapies; Recombinant fusion proteins
- Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Jul 2025 EpimAb Biotherapeutics announces intention to submit an IND application for EM 1034 in 2026 (EpimAb Biotherapeutics pipeline, July 2025)
- 25 Apr 2025 Preclinical trials in Solid tumours in China (Parenteral), prior to April 2025
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Solid tumours presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)